AU727863B2 - Method for generating activated T-cells and antigen-pulsed antigen-presenting cells - Google Patents
Method for generating activated T-cells and antigen-pulsed antigen-presenting cells Download PDFInfo
- Publication number
- AU727863B2 AU727863B2 AU73712/98A AU7371298A AU727863B2 AU 727863 B2 AU727863 B2 AU 727863B2 AU 73712/98 A AU73712/98 A AU 73712/98A AU 7371298 A AU7371298 A AU 7371298A AU 727863 B2 AU727863 B2 AU 727863B2
- Authority
- AU
- Australia
- Prior art keywords
- cells
- antigen
- peptide
- cell
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4256—Tumor associated carbohydrates
- A61K40/4257—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4594997P | 1997-05-08 | 1997-05-08 | |
| US60/045949 | 1997-05-08 | ||
| PCT/US1998/009288 WO1998050527A1 (en) | 1997-05-08 | 1998-05-07 | Method for generating activated t-cells and antigen-pulsed antigen-presenting cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU7371298A AU7371298A (en) | 1998-11-27 |
| AU727863B2 true AU727863B2 (en) | 2001-01-04 |
Family
ID=21940709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU73712/98A Ceased AU727863B2 (en) | 1997-05-08 | 1998-05-07 | Method for generating activated T-cells and antigen-pulsed antigen-presenting cells |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6600012B1 (cg-RX-API-DMAC10.html) |
| EP (3) | EP0986636B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP4480800B2 (cg-RX-API-DMAC10.html) |
| AT (2) | ATE394474T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU727863B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2289742C (cg-RX-API-DMAC10.html) |
| DE (2) | DE69839443D1 (cg-RX-API-DMAC10.html) |
| DK (1) | DK1634949T3 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2357960T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO1998050527A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19906744A1 (de) * | 1999-02-18 | 2000-08-24 | Martin Roecken | Verfahren zur Herstellung antitumoraler Th1-Zellen |
| CA2368967A1 (en) * | 1999-04-09 | 2000-10-19 | Biomira, Inc. | Telomerase-specific cancer vaccine |
| DE19917195B4 (de) * | 1999-04-16 | 2006-09-28 | Immatics Biotechnologies Gmbh | Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor |
| WO2001018035A2 (en) * | 1999-09-08 | 2001-03-15 | Transgene S.A. | Muc-1 derived peptides |
| GB9921337D0 (en) | 1999-09-09 | 1999-11-10 | Axis Genetics Plc | Modified plant viruses |
| GB0007150D0 (en) * | 2000-03-24 | 2000-05-17 | Lamellar Therapeutics Limited | Immunotherapeutic methods and compositions |
| ES2424131T3 (es) * | 2001-03-27 | 2013-09-27 | Oncothyreon Inc. | Vacuna para modular respuestas inmunitarias entre T1 y T2 |
| US7282222B2 (en) | 2002-03-15 | 2007-10-16 | The United States Of America As Represented By The Department Of Veterans Affairs | Methods and compositions for directing cells to target organs |
| EP1572918B1 (en) * | 2002-04-15 | 2011-10-19 | Oncothyreon Inc. | Synthetic glyco-lipo-peptides as vaccines |
| US20060142546A1 (en) * | 2002-09-05 | 2006-06-29 | Franz-Georg Hanisch | Immunogenic muc1 glycopeptides |
| CA2501527A1 (en) * | 2002-10-10 | 2004-04-22 | Catherine A. Phillips | Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope |
| US20050045205A1 (en) * | 2003-08-29 | 2005-03-03 | Stach Steven R. | Apparatus and method for cleaning printed circuit boards |
| GB0322448D0 (en) | 2003-09-25 | 2003-10-29 | Lamellar Therapeutics Ltd | Using lamellar bodies to modify linear biological macro molecules |
| JP5060134B2 (ja) * | 2003-12-12 | 2012-10-31 | ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ | ヒト細胞傷害性Tリンパ球のエピトープ及びそのMUC−1の非VNTR(non−variablenumberoftandemrepeatsequence)由来のアゴニストエピトープ |
| TW201204410A (en) | 2004-04-01 | 2012-02-01 | Oncothyreon Inc | Mucinous glycoprotein (MUC-1) vaccine |
| EP1812052A1 (en) * | 2004-11-02 | 2007-08-01 | Biomedical Research Models, Inc. | Methods of cancer treatment/prevention using cancer cell-specific surface antigens |
| PT2366400E (pt) | 2005-06-28 | 2016-02-02 | Oncothyreon Inc | Método de tratamento de doentes com uma vacina à base de glicoproteína mucinosa (muc-1) |
| WO2010002478A2 (en) | 2008-07-03 | 2010-01-07 | University Of Georgia Research Foundation, Inc. | Glycopeptide and uses thereof |
| CA2637600A1 (en) | 2006-01-17 | 2007-07-26 | Health Research, Inc. | Heteroduplex tracking assay |
| RU2377994C1 (ru) * | 2008-05-21 | 2010-01-10 | Леонид Валентинович Загребин | Способ иммунореабилитации онкозаболеваний |
| US20100059084A1 (en) * | 2008-09-10 | 2010-03-11 | Austin American Technology Corporation | Cleaning and testing ionic cleanliness of electronic assemblies |
| RU2578420C2 (ru) | 2010-05-10 | 2016-03-27 | Эсенд Байофармасьютикалз Пти Лтд | Иммуностимулирующие и вакцинные композиции |
| JP2014518841A (ja) | 2011-02-24 | 2014-08-07 | オンコシレオン インク. | アジュバントを備えたmuc1ベースのグリコリポペプチドワクチン |
| WO2013103658A1 (en) | 2012-01-03 | 2013-07-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Native and agonist ctl epitopes of the muc1 tumor antigen |
| JP2016520073A (ja) | 2013-05-14 | 2016-07-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Muc−1リポペプチドによるワクチン免疫で肺癌を治療する方法 |
| WO2015058831A1 (en) | 2013-10-25 | 2015-04-30 | Merck Patent Gmbh | Elevated biomarker expression in lung cancer patients responding to treatment with muc-1 lipopeptide vaccines |
| CN110325205B (zh) | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| KR20240005989A (ko) | 2017-03-15 | 2024-01-12 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
| GB201812647D0 (en) | 2018-08-03 | 2018-09-19 | Chancellor Masters And Scholars Of The Univ Of Oxford | Viral vectors and methods for the prevention or treatment of cancer |
| JP2022536581A (ja) * | 2019-06-19 | 2022-08-18 | キュー バイオファーマ, インコーポレイテッド | 多量体t細胞調節性ポリペプチド及びその使用方法 |
| IL296209A (en) | 2020-05-12 | 2022-11-01 | Cue Biopharma Inc | Multimeric t-cell modulatory polypeptides and methods of using them |
| JP2023541366A (ja) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ, インコーポレイテッド | 1型真性糖尿病(t1d)を治療するためのmhcクラスii t細胞調節多量体ポリペプチド及びその使用方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2135068T3 (es) | 1994-06-13 | 1999-10-16 | Unilever Nv | Activacion de blanqueantes. |
| DK0765386T3 (en) * | 1994-06-14 | 2015-01-26 | Univ Leland Stanford Junior | Methods for T cell activation in vivo with antigen-incubated dendritic cells |
| AU5849796A (en) * | 1994-12-27 | 1996-08-07 | United Biomedical Inc. | Peptide ratchet libraries for ctl-inducing vaccines and therapeutics |
| AU6330896A (en) * | 1995-06-07 | 1996-12-30 | Governors Of The University Of Alberta, The | A method for eliciting a th1-specific immune response |
| CA2282300C (en) | 1997-02-24 | 2011-08-02 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
-
1998
- 1998-05-07 DE DE69839443T patent/DE69839443D1/de not_active Expired - Lifetime
- 1998-05-07 EP EP98921011A patent/EP0986636B1/en not_active Expired - Lifetime
- 1998-05-07 AT AT98921011T patent/ATE394474T1/de not_active IP Right Cessation
- 1998-05-07 JP JP54847798A patent/JP4480800B2/ja not_active Expired - Fee Related
- 1998-05-07 EP EP05076809A patent/EP1634949B1/en not_active Expired - Lifetime
- 1998-05-07 DE DE69842060T patent/DE69842060D1/de not_active Expired - Lifetime
- 1998-05-07 AU AU73712/98A patent/AU727863B2/en not_active Ceased
- 1998-05-07 EP EP10180388.0A patent/EP2341072A3/en not_active Withdrawn
- 1998-05-07 CA CA2289742A patent/CA2289742C/en not_active Expired - Fee Related
- 1998-05-07 DK DK05076809.2T patent/DK1634949T3/da active
- 1998-05-07 ES ES05076809T patent/ES2357960T3/es not_active Expired - Lifetime
- 1998-05-07 AT AT05076809T patent/ATE491465T1/de active
- 1998-05-07 WO PCT/US1998/009288 patent/WO1998050527A1/en not_active Ceased
-
2000
- 2000-02-03 US US09/497,232 patent/US6600012B1/en not_active Expired - Lifetime
Non-Patent Citations (2)
| Title |
|---|
| AGRAWAL ET AL, JOURNAL OF IMMUNOLOGY, 1996, 157:2089-2095 * |
| GAGLIARDI ET AL, INTERNATIONAL IMMUNOLOGY,'95,7(11):1741-52 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US6600012B1 (en) | 2003-07-29 |
| EP1634949B1 (en) | 2010-12-15 |
| CA2289742C (en) | 2013-07-16 |
| JP2001525668A (ja) | 2001-12-11 |
| JP4480800B2 (ja) | 2010-06-16 |
| EP0986636B1 (en) | 2008-05-07 |
| ATE394474T1 (de) | 2008-05-15 |
| AU7371298A (en) | 1998-11-27 |
| EP1634949A1 (en) | 2006-03-15 |
| DE69842060D1 (de) | 2011-01-27 |
| ES2357960T3 (es) | 2011-05-04 |
| WO1998050527A1 (en) | 1998-11-12 |
| EP2341072A2 (en) | 2011-07-06 |
| CA2289742A1 (en) | 1998-11-12 |
| EP2341072A3 (en) | 2013-10-30 |
| DK1634949T3 (da) | 2011-03-28 |
| DE69839443D1 (de) | 2008-06-19 |
| EP0986636A1 (en) | 2000-03-22 |
| ATE491465T1 (de) | 2011-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0986636B1 (en) | Method for generating activated t-cells and antigen-pulsed antigen-presenting cells | |
| Reddish et al. | Anti‐MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide | |
| Corr et al. | Costimulation provided by DNA immunization enhances antitumor immunity | |
| US6077519A (en) | Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients | |
| TW514530B (en) | Tumor vaccines and methods for their production | |
| US8552145B2 (en) | Vaccine for modulating between T1 and T2 immune responses | |
| Agrawal et al. | Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes. | |
| Hermans et al. | Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge | |
| AU4825700A (en) | Use of soluble costimulatory molecules to enhance immune responses | |
| AU781376B2 (en) | Telomerase-specific cancer vaccine | |
| JP4592702B2 (ja) | NY−ESO−1とアジュバントのinvivo有効性 | |
| AU2002309141A1 (en) | Vaccine for modulating between T1 and T2 immune responses | |
| US20020018806A1 (en) | Lipopeptide adjuvants | |
| KR20030070454A (ko) | 면역 치료용 성숙화된 수지상 세포 백신의 제조방법 | |
| EP1852126B1 (en) | Vaccine for modulating between T1 and T2 immune responses | |
| AU4111999A (en) | Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes |